ArticleJournal of asthma and allergy2021
The Patients' Experience of Severe Asthma Add-On Pharmacotherapies: A Qualitative Descriptive Study.
Article in Journal of asthma and allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- A feasibility randomised controlled trial of Novel Activity Management in severe ASthma-Tailored Exercise (NAMASTE): yoga and mindfulness.BMC pulmonary medicine · 2021Trial
- Asthma in athletes: diagnostic challenges and management strategies.Current opinion in allergy and clinical immunology · 2026Review
- Strategies and Behaviour Change Techniques to Optimise Sedentary Behaviour for People with Severe Asthma: A Nominal Group Technique.Journal of clinical medicine · 2026Article
- Systemic immunologic effects of long-term dupilumab treatment in severe eosinophilic asthma beyond clinical outcomes.Frontiers in allergy · 2026Article
- Review
- Unlocking Asthma Remission: Key Insights From an Expert Roundtable Discussion.Respirology (Carlton, Vic.) · 2025Review
- Digitally mapping the asthma journey-from diagnosis to remission.EClinicalMedicine · 2025Review
- Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma.The European respiratory journal · 2025Article
- Experiences of Oral Corticosteroid Use and Adverse Effects: A National Cross-Sectional Survey of People with Asthma.Patient preference and adherence · 2025Article
- Disease Impact and Perception of Biologics in Adults with Type 2 Inflammation Respiratory Disease: International Survey Results.Patient preference and adherence · 2025Article
- Patient-centred outcomes in severe asthma: fatigue, sleep, physical activity and work.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Integrating hot topics and implementation of treatable traits in asthma.The European respiratory journal · 2024Review
- Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma.Advances in therapy · 2024Article
- Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.Paediatric drugs · 2023Review
- Key Considerations When Addressing Physical Inactivity and Sedentary Behaviour in People with Asthma.Journal of clinical medicine · 2023Review
- Definitions of non-response and response to biological therapy for severe asthma: a systematic review.ERJ open research · 2023Review
- Narrative review to capture patients' perceptions and opinions about non-response and response to biological therapy for severe asthma.The European respiratory journal · 2023Review
- "Life-changing": the experience of super-responders to biologics in severe asthma.BMC pulmonary medicine · 2022Article
- Clinical Characteristics and Disease Burden of Severe Asthma According to Oral Corticosteroid Dependence: Real-World Assessment From the Korean Severe Asthma Registry (KoSAR).Allergy, asthma & immunology research · 2022Article
- Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand.Respirology (Carlton, Vic.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAdd-on therapies for severe asthma are continually emerging with proven efficacy in randomised controlled trials. To date, however, there are no qualitative studies exploring patients' experiences with these treatments. We aimed to understand the experience of patients who were treated with an add-on therapy for their severe asthma. PATIENTS AND
methodsA qualitative descriptive study was conducted, participants were recruited from the respiratory clinics and databases of a tertiary referral hospital. Participants with treatment-refractory severe asthma (n=20) prescribed an add-on therapy for >4 months (75% mepolizumab; 25% omalizumab, and 25% macrolide) were recruited. Qualitative semi-structured interviews were conducted, with interviews thematically analysed.
resultsParticipants' mean (SD) age was 59.5 (15.3) years, and 50% were male. Participants reported 4.5 (2.3) exacerbations in the past year. Asthma Control Questionnaire score was 2.0 (1.4). The monoclonal add-on therapies had been prescribed for a median (IQR) of 12.5 (7.0, 24.0) months. Experience was captured in four emergent themes: "Life is just easier" provided an overall message that the add-on therapy made the participants' life easier in terms of increasing participation, levelling out symptoms, providing more energy and reducing healthcare use. "Prednisone: A necessary evil" was discussed, particularly in terms of dose and dependence and damaging side effects. The theme "worry and hope for the future" referenced treatment non-response or cessation of effect which was discussed by some participants. Finally, "holistic care" was centred on the sentiment that the participant's asthma management and overall health were not related to one aspect or medication alone.
conclusionPatients with severe asthma experience vast improvements in quality-of-life and life participation with add-on therapies, but there remains a significant burden related to oral corticosteroids and incomplete treatment responses. Addressing this residual burden is an important area for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.